Stress proteins and peptides and methods of use thereof

Details Stress proteins and peptides and methods of use thereof Stress proteins and peptides and methods of use thereof

2005-03-14

2009-10-27

Navarro, Mark (Department: 1645)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S350000, C424S185100

Reexamination Certificate

active

07608683

ABSTRACT:
Provided are HLA pan DR-binding peptides and methods of using such peptides to modulate, block, or inhibit immune responses to effect treatment of immune-mediated diseases and conditions, such as inflammatory and autoimmune diseases, cancer, and microbial infections. These peptides and methods are also useful diagnostically to screen peptide or peptide analogs that can inhibit the pathogenic immune response or up-regulate an immune response against aberrant or invading cells, to monitor efficacy for therapeutic treatments, and to identify other agents that may be effective to inhibit or otherwise modulate an immune response such as by altering T cell functional phenotype, and even more particularly by modulating the regulatory phenotype of regulatory T cells and/or inducing emergence of T cells with a different functional phenotype.

REFERENCES:
patent: 4654419 (1987-03-01), Vaughan et al.
patent: 4683295 (1987-07-01), Carson
patent: 4732757 (1988-03-01), Stolle et al.
patent: 5116725 (1992-05-01), Vaughan et al.
patent: 5310732 (1994-05-01), Carson et al.
patent: 5541164 (1996-07-01), Carson et al.
patent: 5728385 (1998-03-01), Classen
patent: 5773570 (1998-06-01), Carson et al.
patent: 5891435 (1999-04-01), Muir et al.
patent: 5922567 (1999-07-01), Au-Young et al.
patent: 5928644 (1999-07-01), Russell-Jones et al.
patent: 5993803 (1999-11-01), Cohen et al.
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6455503 (2002-09-01), Srivastava
patent: 6610836 (2003-08-01), Breton et al.
patent: 6989146 (2006-01-01), Albani et al.
patent: 2002/0146759 (2002-10-01), Albani et al.
patent: 2006/0093574 (2006-05-01), Albani et al.
patent: WO 90/14835 (1990-12-01), None
patent: WO 95/25744 (1995-09-01), None
patent: WO 95/31984 (1995-11-01), None
patent: WO 96/10039 (1996-04-01), None
patent: WO 97/11966 (1997-04-01), None
patent: WO 97/34002 (1997-09-01), None
patent: WO 99/61916 (1999-12-01), None
patent: WO 01/16174 (2001-03-01), None
patent: WO 03/026579 (2003-04-01), None
Guichard et al (PNAS USA, vol. 91, Oct. 1994, pp. 9765-9769).
Albani, S., et al., “A Multistep Molecular Mimicry Hypothesis for the Pathogenesis of Rheumatoid Arthritis,”Immunology Today, vol. 17, No. 10, pp. 466-470, Oct. 1996.
Albani, et al., “Genetic and Environmental Factors in the Immune Pathogenesis of Rheumatoid Arthritis,”Rheumatic Disease Clinics of North America, 18/4:729-740, 1992.
Albani et al, “HLA Binding Studies Support a Role for the QKRAA Susceptibility Sequence to Rheumatoid Arthritis (RA) in Positive Selection and Activation of Pathogenic T Lymphocytes,”Arthritis and Rheumatism, 38/9 Suppl., p. S181, Abstract#173, 1995.
Albani, S., et al., “Immune Responses to theEscherichia colidnaJ Heat Shock Protein in Juvenile Rheumatoid Arthritis and their Correlation with Disease Activity,”The Journal of Pediatrics, vol. 124, No. 4, pp. 561-565, Apr. 1994.
Albani, S., et al., “Molecular Basis for the Association Between HLA DR4 and Rheumatoid Arthritis. From the Shared Epitope Hypothesis to a Peptidic Model of Rheumatoid Arthritis,”Clin. Biochem.vol. 25, pp. 209-212, 1992.
Albani, S., et al., “Positive Selection in Autoimmunity: Abnormal Immune Responses to a Bacterial dnaJ Antigen Determinant in Patients with Early Rheumatoid Arthritis,”Nature Medicine, vol. 1, No. 5, pp. 448-452, 1995.
Albani, S., et al., “The Susceptibility Sequence to Rheumatoid Arthritis is a Cross-Reactive B Cell Epitope Shared by theEscherichia coliHeat Shock Protein dnaJ and the Histocompatibility Leukocyte Antigen DRB10401 Molecule,”J. Clin. Invest., vol. 89, pp. 327-331, 1992.
Anderton, S.M., et al. “Activation of T Cells Recognizing Self 60-kD Heat Shock Protein Can Protect Against Experimental Arthritis,”J. Exp. Med., vol. 181, pp. 943-952, Mar. 1995.
Anderton et al, “Differential Mycobacterial 65-kDa Heat Shock Protein T Cell Epitope Recognition after Adjuvant Arthritis-Inducing or Protective Immunization Protocols1,”J. Immunology152:3656-64, 1994.
Asseldonk, M., et al., “Cloning, Nucleotide Sequence, and Regulatory Analysis of theLactococcus lactis dnaJGene,”,Journal of Bacteriology, 175(6), pp. 1637-1644, Mar. 1993.
Auger, I., et al., “HLA-DR4 and HLA-DR10 Motifs that Carry Susceptibility to Rheumatoid Arthritis Bind 70-kD Heat Shock Proteins,”Nature Medicine, vol. 2, No. 3, pp. 306-310, Mar. 1996.
Bardwell, J.C.A., et al., “The Nucleotide Sequence of theEscherichia coliK12 dnaJ+ Gene,”The Journal of Biological Chemistry, vol. 261, No. 4, pp. 1782-1785, Feb. 5, 1986.
Bonnin, D., et al., “MHC-Derived Peptides Drive Positive T Cell Selection in the Thymus: from a Physiological System to an HLA DRB1 0401 Transgenic Mouse Model for Rheumatoid Arthritis?”,Arthritis and Rheumatism, vol. 39, No. 9 Suppl., p. S160, Oct. 1996.
Brackertz et al, “OM-8980 in Rheumatoid Arthritis: A 6-Month Double Blind Placebo Controlled Multicenter Study,”Journal of Rheumatology, vol. 16, pp. 19-23, 1989.
DeGraeff-Meeder, E.R., et al., “Recognition of Human 60kD Heat Shock Protein by Mononuclear Cells from Patients with Juvenile Chronic Arthritis,”The Lancet, vol. 337, pp. 1368-1372, Jun. 8, 1991.
Fairchild, P., et al., “Peptide-MHC Interaction in Autoimmunity,”Current Opinion in Immunology, vol. 4, pp. 748-753, 1992.
Geluk et al., “Identification of HLA Class II-restricted Determinants of Mycobacterium Tuberculosis-derived Proteins by Using HLA-Transgenic, Class II-deficient Mice,”Proceedings of the National Academy of Science, vol. 95, pp. 10797-10802, 1998.
La Cava, A., et al., “The QKRAA Disease Susceptibility Sequence for Rheumatoid Arthritis (RA) is a B Cell Epitope Shared by the Epstein-Barr Virus (EBV) Protein gp110 and theE. coliHeat Shock Protein dnaJ Possible Implications for Disease Pathogenesis,”Arthritis&Rheum.36(9) Suppl. pp. S127 Abstract 1993.
Life, P.F., et al., “Synovial Fluid Antigen-Presenting Cells Unmask Peripheral Blood T Cell Responses to Bacterial Antigens in Inflammatory Arthritis,”Clin. Exp. Immunol.vol. 79, pp. 189-194, 1990.
Marsh, S.G.E., et al, “HLA Class II Nucleotide Sequences, 1991,”Tissue Antigens, vol. 37, pp. 181-189, 1991.
Meeker, et al. “Analysis of Human Antibodies Epitopes on the 65-Kilodalton Protein ofMycobacterium lepareby Using Synthetic Peptides”,Infection and Immunity, American Society for Microbiology, Washington, D.C, US, vol. 57, No. 12, 3689-3694, Dec. 1989.
Nepom, G., “Prediction of Susceptibility to Rheumatoid Arthritis by Human Leukocyte Antigen Genotying”Rheumatic Disease Clinics of North America, vol. 18, No. 4, pp. 785-792, Nov. 1992.
Ohki, M., et al., “Nucleotide Sequence of theEscherichia colidnaJ Gene and Purification of the Gene Product”, The Journal of Biological Chemistry, vol. 261, No. 4, pp. 1778-1781, 1986.
Plotkin, S.A., et al., “New Technologies for Making Vaccines,”Vaccines, pp. 568-575, 1988.
Prakken et al. “Epitope: Mapping of Hsp60 T Cell Responses in Children with Pauci Articular Juvenile Rheumatoid Arthritis by Prediction of PAN-HLA DR. Binding Sites”,Arthritis and Rheumatism, Lippincott, Philadelphia, US, vol. 42, No. 9 Supplement, S229, Sep. 1999.
Prakken, et al., “Peptide-induced nasal tolerances for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis”,Proceedings of the National Academy of Sciences, USA, vol. 94, 3284-3289, Apr. 1997.
Prakken et al., “Identification of Pan-DR Binding T Cell Epitopes of Human and Mycobacterial hsp60 in Patients with Juvenile Idiopathic Arthritis”,Conference of Immunologist, p. 1, Jan. 2001.
Silver, P.A., et al. “Eukaryotic DnaJ Homologs and the Specificity of Hsp70 Activity,”Cell, vol. 74, pp. 5-6, Jul. 16, 1993.

Affiliated with

Also associated with

Rating

Stress proteins and peptides and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stress proteins and peptides and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stress proteins and peptides and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4101003